Across TCGA pan-cancer cohorts, RPL37A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL37A data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL37A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL37A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where RPL37A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.785	0.475	.018	14	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	9	view →
UCEC	OS	Tertile	II,III,IV	0.559	1.000	.022	8	view →
PDAC	DFS	Tertile	All	0.482	0.326	.018	8	view →
HNSC	DFS	Quartile	III,IV	0.950	0.702	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL37A tumor-vs-normal RNA expression · all RPL37A data types